Latest gastrointestinal stromal tumor Stories
A drug that is already an approved therapy for some cancers also might be an effective secondary treatment for a rare tumor of the gastrointestinal tract.
A research article to be published on July 21, 2009 in the World Journal of Gastroenterology addresses this question. This research led by Professor Kim and his colleagues in Pusan National University, South Korea.
Survival rate racial differences for gastrointestinal tumors are narrowing between African-Americans and whites, U.S. researchers said.
New research published in the July issue of the Journal of the American College of Surgeons reveals that African Americans with gastrointestinal stromal tumors
Company Expands Diagnostic Services with K9 Clone DOG-1 Immunohistochemical and H. pylori Monoclonal Antibody Tests LAKEWOOD, N.J., June 1 /PRNewswire/ -- PLUS Diagnostics, a leading U.S.
Partner Keryx to present Phase 2 data on perifosine for multiple cancers QUEBEC CITY, May 19 /PRNewswire-FirstCall/ - AEterna Zentaris Inc.
Results Will be Reported from Phase 2 Studies Evaluating KRX-0401 in Advanced Renal Cell Carcinoma, Colorectal Cancer and Gastrointestinal Stromal Tumors (GIST) NEW YORK, May 18 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc.
Researchers at Fox Chase Cancer Center uncovered a genetic pattern that may help predict how gastrointestinal stromal tumor (GIST) patients respond to the targeted therapy imatinib mesylate (Gleevec). Moreover, their findings point to genes that could be suppressed in order to make these tumors respond more readily to imatinib.
FRIMLEY, England, May 8 /PRNewswire/ -- - Glivec(R) (imatinib) Now Approved in the UK for Post-Surgery Treatment of Patients With KIT (CD117)-Positive Gastrointestinal Stromal Tumours (GIST), who are at Significant Risk of the Cancer Returning After Surgery(1) - Use of Glivec(R) After Surgery Significantly Reduces Risk of Cancer Relapse(2) - If Untreated After Surgery, 50% of patients Will Experience Their Cancer Returning Within Two Years(3,4) Glivec(R) has been approved...
- Estimated one-year, recurrence-free survival was 98% for Kit-positive GIST patients taking Gleevec vs.
- totally perplexed and mixed up.